Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus GILDESS 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus GILDESS 1 20.
ENSKYCE vs GILDESS 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (GnRH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive